News
Q3 2025 Earnings Call Transcript August 13, 2025 Organigram Global Inc. misses on earnings expectations. Reported EPS is ...
Organigram's Q3 sales rose 72% to $51.14 million, driven by Motif acquisition and global demand, with margin gains and positive cash flow expected.
Zacks Investment Research on MSN2d
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates
OrganiGram (OGI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.02 per share a year ago. These figures are ...
TORONTO, February 04, 2025--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of ...
Analysts expect OrganiGram Holdings to report an earnings per share (EPS) of $-0.01. The announcement from OrganiGram Holdings is eagerly anticipated, with investors seeking news of surpassing ...
Accelerates Organigram’s R&D and product pipeline development, provides meaningful capital injection of ~C$221 million and strengthens Organigram’s ability to compete in existing markets and ...
Organigram Maintains Strong Cash Position Prior to the Equity Top-Up, Organigram e njoyed a strong cash position of CA$168 million reported as at the end of Fiscal Q1-2022 (November 30, 2021).
Organigram also inked a deal with Serbia-based Eviana to purchase up to 25% of its hemp-derived CBD oil. The company views this agreement as a key part of its strategy to serve the broader ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback